Atara Biotherapeutics, Inc. (0HIY.L)
USD 10.43
(-0.02%)
USD 10.43
(-0.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.57 Million USD | -86.51% |
| 2022 | 63.57 Million USD | 212.55% |
| 2021 | 20.34 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 28.64 Million USD | 4.69% |
| 2024 Q1 | 27.35 Million USD | 543.39% |
| 2023 Q1 | 1.22 Million USD | 454.75% |
| 2023 FY | 8.57 Million USD | -86.51% |
| 2023 Q4 | 4.25 Million USD | 98.88% |
| 2023 Q3 | 2.13 Million USD | 123.41% |
| 2023 Q2 | 957 Thousand USD | -21.94% |
| 2022 Q4 | 221 Thousand USD | -95.04% |
| 2022 Q1 | 7.31 Million USD | -3.1% |
| 2022 Q2 | 51.57 Million USD | 605.21% |
| 2022 FY | 63.57 Million USD | 212.55% |
| 2022 Q3 | 4.45 Million USD | -91.36% |
| 2021 Q3 | 5.37 Million USD | 38.76% |
| 2021 Q4 | 7.54 Million USD | 40.56% |
| 2021 Q1 | 3.55 Million USD | -99.01% |
| 2021 FY | 20.34 Million USD | 0.0% |
| 2021 Q2 | 3.87 Million USD | 8.95% |
| 2020 Q4 | 358.19 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 89.026% |
| Dynavax Technologies Corporation | 232.28 Million USD | 96.309% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 98.589% |
| Perrigo Company plc | 4.65 Billion USD | 99.816% |
| Illumina, Inc. | 4.5 Billion USD | 99.81% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.98% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -621.026% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.994% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.943% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 93.252% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.935% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 99.71% |
| Biogen Inc. | 9.83 Billion USD | 99.913% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 95.135% |
| Evolus, Inc. | 202.08 Million USD | 95.758% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 59.114% |
| bluebird bio, Inc. | 29.49 Million USD | 70.936% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 92.631% |
| FibroGen, Inc. | 147.75 Million USD | 94.198% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 99.875% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 228.898% |
| Geron Corporation | 237 Thousand USD | -3517.3% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.531% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 97.853% |
| Myriad Genetics, Inc. | 678.4 Million USD | 98.736% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 76.367% |
| Zoetis Inc. | 8.54 Billion USD | 99.9% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -144.943% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 99.774% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.646% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.913% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 98.912% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | 90.487% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 96.832% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 72.566% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.31% |
| OPKO Health, Inc. | 863.49 Million USD | 99.007% |
| Exelixis, Inc. | 1.83 Billion USD | 99.532% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.546% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 98.223% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 45.888% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 96.562% |
| Insmed Incorporated | 305.2 Million USD | 97.191% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 98.966% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 68.039% |
| TG Therapeutics, Inc. | 233.66 Million USD | 96.331% |
| Incyte Corporation | 3.69 Billion USD | 99.768% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 99.183% |